allosteric mutant-EGFR inhibitor
in vivo efficacy in osimertinib-resistant xenograft models
from opt. of prev. disclosed EGFR inhibitor
Nat. Cancer
Dana-Farber Cancer Institute, Boston, MA
JBJ-09-063
Context. JBJ-09-063 (Dana-Farber Cancer Institute) is an oral allosteric EGFR inhibitor currently in pre-clinical development for the treatment of EGFR L858R-mutant non-small cell lung cancer (NSCLC). Despite the availability…